The Effects of Angle Kappa on Clinical Outcomes With the PanOptix Intraocular Lens

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-21

Study Completion Date

2021-04-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Angle Kappa is considered a potential factor in explaining suboptimal outcomes with intraocular lenses (IOLs), particularly multifocal IOLs. Some evidence suggests this is not the case. This study was designed to investigate correlations between angle kappa and post-surgical outcomes with a trifocal IOL.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Studies of the Angle Kappa and the Angle Alpha

NCT04886219

No Eye Disorder

COMPLETED

Changes of Angle Kappa After Implantation of Multifocal Intraocular Lenses

NCT03297086

Cataract Presbyopia

COMPLETED NA

Optimizing the Assessment of Refractive Outcomes After Cataract Surgery

NCT02842151

Cataract

COMPLETED NA

Spectacle Independence and Overall Satisfaction With AcrySof® Panoptix® Toric Intraocular Lens

NCT04128514

Cataract

TERMINATED

Wavefront Analysis and Contrast Sensitivity After Cataract Surgery With Akreos Advanced Optics Intraocular Lens Implantation

NCT00863759

Lens Implantation, Intraocular

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main complaint of patients who received a presbyopia correcting lens (regardless of the design) are visual disturbances such as glare, halos (rings around lights), starbursts (rays around light sources), mainly at night. The degree of limitation or how bothered patients are varies from patient to patient. To explain these symptoms different theories have been proposed including splitting the light into different focal points which decreases the intensity of the light reaching the retina. Most factors are common to all patients who received the lens; however, patients are not equally affected by these symptoms. Angle kappa has been considered a factor. Angle κ is the angle between the visual axis (straight line that passes through both the center of the pupil and the center of the fovea) and the pupillary axis (perpendicular line to the surface of the cornea that passes through the center of the pupil).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pseudophakia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PanOptix

Participants will receive the PanOptix intraocular lens.

Angle Kappa

Intervention Type DIAGNOSTIC_TEST

Angle kappa will be measured using the OPD III scan.

Visual disturbance questionnaire.

Intervention Type OTHER

Questionnaire evaluating visual disturbances.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Angle Kappa

Angle kappa will be measured using the OPD III scan.

Intervention Type DIAGNOSTIC_TEST

Visual disturbance questionnaire.

Questionnaire evaluating visual disturbances.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is undergoing bilateral lens extraction with intraocular lens implantation (PanOptix lens).
2. Willing and able to provide written informed consent for participation in the study
3. Willing and able to comply with scheduled visits and other study procedures.
4. Scheduled to undergo standard cataract surgery with topical anesthesia in both eyes within 6 to 30 days between surgeries.
5. Subjects who require an IOL power in the range of +6.0 D to +30.0 D only.
6. Subjects who require a TFNT00 or TFNT30 to TFNT60 IOL.
7. Potential postoperative visual acuity of 0.2 logMAR (20/32 Snellen) or better in both eyes.

Exclusion Criteria

1. Severe preoperative ocular pathology
2. Subjects who require a higher toric power than the one available (TFNT60).
3. Uncontrolled diabetes.
4. Use of any systemic or topical drug known to interfere with visual performance.
5. Contact lens use during the active treatment portion of the trial.
6. Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.
7. Clinically significant corneal dystrophy
8. History of chronic intraocular inflammation.
9. History of retinal detachment.
10. Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules.
11. Previous ocular surgery.
12. Severe dry eye
13. Pupil abnormalities
14. Anesthesia other than topical anesthesia (i.e. retrobulbar, general, etc).
15. Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results.
16. Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No